Transcription of fuboTV Inc. (FUBO) Earnings Call for Q2 2025
Sure! Here’s the rewritten content with the requested adjustments:
fuboTV Inc. (NYSE:FUBO) Q2 2025 Earnings Conference Call
August 8, 2025
8:30 AM ET
Company Participants
Ameet Padte - Senior VP of FP&A, Corporate Development & Investor Relations
David Gandler - Co-Founder, President, CEO & Director
John Janedis - CFO & Principal Accounting Officer
Conference Call Participants
Alicia Spring Reese - Wedbush Securities Inc., Research Division
Douglas Middleton - Huber Research Partners, LLC
Joseph Louis Spiezio - BTIG, LLC, Research Division
Laura Anne Martin - Needham & Company, LLC, Research Division
Patrick William Sholl - Barrington Research Associates, Inc., Research Division
Operator
Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to Fubo 2Q '25 Earnings Call. [Operator Instructions] I would now like to turn the call over to Ameet Padte, SVP, FP&A, Corporate Development and Investor Relations. Please go ahead.
Ameet Padte
Thank you for joining us to discuss Fubo's second quarter 2025 results. With me today is David Gandler, Co-Founder and CEO of Fubo; and John Janedis, CFO of Fubo. Full details of our results and additional management commentary are available in our earnings release and letter to shareholders, which can be found in the Investor Relations section of our website.
Before we begin, let me quickly review the format of today's call. David will start with some brief remarks on the quarter and our business, and John will cover the financials. Then we will turn the call over to the analysts for Q&A. I would like to remind everyone that the following discussion may contain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements regarding our financial condition, anticipated financial performance, business strategy and plans, including our pending business combination and our products and subscription packages, market, industry...If you need any further modifications, feel free to ask!
